Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oriel Therapeutics Inc.

Division of Novartis AG
www.orieltherapeutics.com

Latest From Oriel Therapeutics Inc.

Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted

The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker.

Approvals Biosimilars

Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted

The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker.

Approvals Biosimilars

Deals Shaping the Medical Industry (05/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Oriel Therapeutics Inc.

Oriel Therapeutics Inc. hopes to overcome the limitations of current dry powder inhalers with an electronic device that aerosolizes dry powder drugs that waft in consistently precise amounts into the user's natural airstream.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Richard Fuller, MD, CEO
    Thomas J Sekel, CFO
    Paul J Atkins, PhD, Pres. & COO
    Anthony J Hickey, PhD, CSO
  • Contact Info
  • Oriel Therapeutics Inc.
    Phone: (919) 313-1290
    PO Box 14087
    Research Triangle Park, NC 27709
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register